These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 1667252)
1. In vivo evaluation of NM441, a new thiazeto-quinoline derivative. Ozaki M; Matsuda M; Tomii Y; Kimura K; Segawa J; Kitano M; Kise M; Shibata K; Otsuki M; Nishino T Antimicrob Agents Chemother; 1991 Dec; 35(12):2496-9. PubMed ID: 1667252 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice. Tomii Y; Ozaki M; Matsuda M; Honmura T; Nishimura I; Yamaguchi R; Adachi T; Okawa Y; Nishino T Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794 [TBL] [Abstract][Full Text] [Related]
3. In vivo antibacterial activity of a prodrug of NM394, a thiazetoquinoline carboxylic acid derivative. Ozaki M; Tomii Y; Matsuda M; Segawa J; Kitano M; Kise M; Nishino T Chemotherapy; 1998; 44(1):21-30. PubMed ID: 9444405 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. Nakashima M; Uematsu T; Kosuge K; Okuyama Y; Morino A; Ozaki M; Takebe Y J Clin Pharmacol; 1994 Sep; 34(9):930-7. PubMed ID: 7983237 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration. Okuyama Y; Momota K; Morino A Arzneimittelforschung; 1997 Mar; 47(3):276-84. PubMed ID: 9105546 [TBL] [Abstract][Full Text] [Related]
6. [In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin]. Shimizu M; Tabata M; Hara T; Araake M; Watabe H; Nishino T Jpn J Antibiot; 2002 Dec; 55(6):791-9. PubMed ID: 12621733 [TBL] [Abstract][Full Text] [Related]
7. Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone. Yoshida T; Mitsuhashi S Antimicrob Agents Chemother; 1993 Apr; 37(4):793-800. PubMed ID: 8388199 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of prulifloxacin. 3rd communication: metabolism in rats, dogs and monkeys. Okuyama Y; Morino A Arzneimittelforschung; 1997 Mar; 47(3):293-8. PubMed ID: 9105548 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of prulifloxacin. 2nd communication: pharmacokinetics and effect on hepatic drug-metabolizing enzyme activities after repeated administration and transfer into fetus and milk after a single administration in rats. Okuyama Y; Momota K; Morino A Arzneimittelforschung; 1997 Mar; 47(3):285-92. PubMed ID: 9105547 [TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Hosaka M; Yasue T; Fukuda H; Tomizawa H; Aoyama H; Hirai K Antimicrob Agents Chemother; 1992 Oct; 36(10):2108-17. PubMed ID: 1332587 [TBL] [Abstract][Full Text] [Related]
12. [In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone]. Araake M; Hara T; Watabe H; Nishino T Jpn J Antibiot; 2002 Dec; 55(6):778-90. PubMed ID: 12621732 [TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116. Imada T; Miyazaki S; Nishida M; Yamaguchi K; Goto S Antimicrob Agents Chemother; 1992 Mar; 36(3):573-9. PubMed ID: 1320364 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections. Wakebe H; Imada T; Yoneda H; Mukai F; Ohguro K; Ohmori K; Tamaoka H; Yabuuchi Y Antimicrob Agents Chemother; 1994 Oct; 38(10):2340-5. PubMed ID: 7840567 [TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo antibacterial activities of E-4868, a new fluoroquinolone with a 7-azetidin ring substituent. Guinea J; Robert M; Gargallo-Viola D; Xicota MA; Garcia J; Tudela E; Esteve M; Coll R; Pares M; Roser R Antimicrob Agents Chemother; 1993 Apr; 37(4):868-74. PubMed ID: 8388202 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 in experimentally infected normal and alloxan-induced diabetic mice. Obana Y; Nishino T Drugs Exp Clin Res; 1988; 14(5):327-31. PubMed ID: 3219995 [TBL] [Abstract][Full Text] [Related]
17. [Single-dose toxicity studies of prulifloxacin (NM441) in mice, rats and dogs and the active metabolite (NM394) in rats]. Shimazu H; Ishikawa Y; Nishiguchi Y; Yoshida M; Iwakura K; Sumi N; Shindo Y J Toxicol Sci; 1996 Jun; 21 Suppl 1():33-44. PubMed ID: 8709168 [TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Nakamura S; Minami A; Nakata K; Kurobe N; Kouno K; Sakaguchi Y; Kashimoto S; Yoshida H; Kojima T; Ohue T Antimicrob Agents Chemother; 1989 Aug; 33(8):1167-73. PubMed ID: 2802544 [TBL] [Abstract][Full Text] [Related]
19. Effects of new quinolones on Mycoplasma pneumoniae-infected hamsters. Arai S; Gohara Y; Akashi A; Kuwano K; Nishimoto M; Yano T; Oizumi K; Takeda K; Yamaguchi T Antimicrob Agents Chemother; 1993 Feb; 37(2):287-92. PubMed ID: 8383942 [TBL] [Abstract][Full Text] [Related]
20. In vivo activity of ciprofloxacin, ofloxacin, norfloxacin and pipemidic acid against Escherichia coli infections in mice. Obana Y; Nishino T Drugs Exp Clin Res; 1989; 15(2):53-8. PubMed ID: 2661182 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]